Salvatore Privitera Sells 3,657 Shares of AtriCure (NASDAQ:ATRC) Stock

Key Points

• Insider sale: Salvatore Privitera sold 3,657 AtriCure shares for $201,135 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 2.42% to 147,264 shares. He also sold 7,763 shares earlier in September.
• Financial performance: AtriCure reported quarterly EPS of $0.18 and revenue of $153.6 million, exceeding analysts’ $151.8 million estimate. The company expects fiscal 2026 EPS of $0.24 to $0.32.
• Analyst sentiment remains positive: Piper Sandler raised its price target to $60 and BTIG increased its target to $55; the stock carries a “Moderate Buy” consensus rating with an average target of $52.

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) insider Salvatore Privitera sold 3,657 shares of the business's stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $55.00, for a total value of $201,135.00. Following the sale, the insider owned 147,264 shares of the company's stock, valued at approximately $8,099,520. The trade was a 2.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Salvatore Privitera also recently made the following trade(s):

• On Wednesday, September 2nd, Salvatore Privitera sold 7,763 shares of AtriCure stock. The shares were sold at an average price of $52.50, for a total value of $407,557.50.

AtriCure Trading Down 0.2%

AtriCure stock traded down $0.10 during midday trading on Thursday, hitting $52.93. 121,522 shares of the stock were exchanged, compared to its average volume of 800,797. The company has a fifty day simple moving average of $41.54 and a two-hundred day simple moving average of $33.26. The stock has a market capitalization of $2.69 billion, a PE ratio of 252.07 and a beta of 1.26. AtriCure, Inc. has a 52 week low of $25.36 and a 52 week high of $55.72. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The business had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period last year, the firm earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities research analysts anticipate that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Weiss Ratings upgraded shares of AtriCure from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 19th. Citigroup reiterated a "market outperform" rating on shares of AtriCure in a research report on Tuesday, July 21st. Piper Sandler lifted their price objective on AtriCure from $50.00 to $60.00 and gave the company an "overweight" rating in a research note on Thursday, August 27th. Raymond James Financial set a $52.00 price target on AtriCure in a report on Tuesday, July 21st. Finally, BTIG Research upped their price objective on shares of AtriCure from $45.00 to $55.00 and gave the stock a "buy" rating in a research report on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, AtriCure currently has an average rating of "Moderate Buy" and an average target price of $52.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ATRC. Geneos Wealth Management Inc. bought a new stake in shares of AtriCure in the 2nd quarter valued at about $37,000. Harbor Investment Advisory LLC purchased a new position in AtriCure in the 2nd quarter worth approximately $40,000. Allworth Financial LP purchased a new position in AtriCure in the 2nd quarter worth approximately $43,000. Integrated Wealth Concepts LLC bought a new stake in AtriCure in the second quarter valued at approximately $46,000. Finally, Smartleaf Asset Management LLC boosted its stake in shares of AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company's stock valued at $46,000 after purchasing an additional 429 shares during the period. 99.11% of the stock is owned by institutional investors.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.